<DOC>
	<DOCNO>NCT01524380</DOCNO>
	<brief_summary>A double-blind , randomize , placebo-controlled trial ginkgo biloba extract ( Egb-761 ) add-on therapy risperidone compare risperidone plus placebo treatment 200 treatment-naive first-episode patient schizophrenia . The study address immune dysfunction hypothesis schizophrenia .</brief_summary>
	<brief_title>Ginkgo Biloba Extract Schizophrenia</brief_title>
	<detailed_description>OBJECTIVE : There evidence excessive free radical production oxidative stress may involve pathophysiology patient schizophrenia . The investigator hypothesize antioxidant therapy use add-on agent together well-proven antipsychotic drug may favorable effect schizophrenic patient . METHODS : 1 . Clinical Trial : This randomize , double-blind parallel control trial treatment-naive first-episode patient schizophrenia . The study consist 1-week stabilization phase , follow 10 week double-blind treatment . The total trial duration 11 week . 2 . Medications : Eligible patient randomly assign either capsulized EGb ( 240mg.day ) identically capsulize placebo addition risperidone ( 2-6mg/day ) double-blind fashion . 3 . Assessment Procedures : 3.1 . Primary Outcome Variable-psychopathology : Assessment instrument include Positive Negative Syndrome Scale ( PANSS ) , Clinical Global Impression ( CGI ) . Patients interview screen , baseline every two week . 3.2 . Cognitive test : A comprehensive battery test encompass cognitive domain executive function , attention , memory , perception , general intellect administer twice baseline end 10-week treatment trained psychologist . Scoring follow standardize procedure . 3.3 . Side Effects : Parkinsonism rat Simpson-Angus Scale extrapyramidal side effect . The Abnormal Involuntary Movement Scale ( AIMS ) choose assess tardive dyskinesia ( TD ) severity . All AIMS Simpson-Angus Rating Scales administer investigator baseline baseline , week 5 week 10 . 3.4 . Plasma Measures : Venous blood forearm vein collect healthy control patient schizophrenia 7 9 a.m. follow overnight fast . Serum Plasma malondialdehyde ( MDA ) level superoxide dismutase ( SOD ) , glutathione peroxidase ( GSH-Px ) catalase ( CAT ) activity analyze use establish procedure .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia schizophreniform disorder ; Duration symptom longer 60 month ; No prior treatment antipsychotic medication , previously treat , total lifetime usage le 14 day ; Between 16 40 year age ; Current psychotic symptom moderate severity . A DSMIV Axis I diagnosis schizophrenia schizophreniform ; Documented disease central nervous system interfere trial assessment include , limited stroke , tumor , Parkinson 's disease , Huntington 's disease , seizure disorder , history brain trauma result significant impairment , chronic , infection ; Acute , unstable and/or significant untreated medical illness ( e.g. , infection , unstable diabetes , uncontrolled hypertension ) ; A clinically significant ECG abnormality opinion investigator ; Pregnant breastfeed female ; Use disallow concomitant therapy ; History severe allergy hypersensitivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>clinical trial</keyword>
	<keyword>risperidone</keyword>
	<keyword>ginkgo biloba extract</keyword>
	<keyword>antioxidant</keyword>
</DOC>